Zevra Therapeu
Zevra Therapeutics Inc is an American commercial-stage rare disease biopharmaceutical company (formerly operating as KemPharm) focused on the discovery, development, and commercialization of proprietary therapeutics for patients suffering from rare and niche diseases with significant unmet medical needs, prominently featuring approved products such as arimoclomol for Niemann-Pick disease type C and KP1077 for narcolepsy. The company utilizes proprietary drug delivery and prodrug technologies to improve the clinical profile and efficacy of therapeutic compounds. Its core business operations encompass rare disease drug development, clinical trial execution, FDA regulatory navigation, and commercial pharmaceutical distribution. Revenue is derived primarily from specialty pharmaceutical product sales and milestone licensing agreements. Zevra Therapeutics holds a leading market position in rare disease therapeutics and prodrug engineering. The company is headquartered in Celebration, Florida, United States, and its common stock trades on the Nasdaq Global Market.
2 of the funds FundTelligence covers report a position in Zevra Therapeu.
- Legal name
- ZEVRA THERAPEU
- Sector
- Health Care
- Country
- United States
- Funds holding it
- 2
Funds holding Zevra Therapeu
- FTGF Royce US Smaller Companies Fund — Franklin Templeton · 0.46 % (full portfolio disclosed, September 2026)
- BlackRock iShares NASDAQ US Biotechnology UCITS ETF — BlackRock · 0.05 % (full portfolio disclosed, October 2026)